典型文献
Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate
文献摘要：
Dear Editor,
Although the incidence of prostate cancer (PCa) has decreased in recent decades in Western countries, it has gradually increased in China due to the increasingly longer life expectancy and more popular westernized diet[1]. Androgen deprivation therapy (ADT) has been a cornerstone in the treatment of advanced PCa. However, most patients develop resistance to ADT within a median duration of 18–24 months, which is defined as castration-resistant prostate cancer (CRPC). Abiraterone acetate (AA), an inhibitor of the androgen biosynthesis enzyme CYP17 (17-a-hydroxylase and C17,20-lyase), has been approved for the treatment of metastatic CRPC, although not all patients benefit from AA treatment[2,3]. Therefore, identifying patients who will respond to AA treatment and the time to second-line therapy is of great importance.
文献关键词：
中图分类号：
作者姓名：
Jiang-Yi Wang;Guo-Peng Yu;Long Li;Guo-Wen Lin;Ding-Wei Ye
作者机构：
Department of Urology,Fudan University Shanghai Cancer Center,270 Dong'an Road,Shanghai 200032,China;Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China;Department of Urology,Shanghai Ninth People's Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200011,China
文献出处：
引用格式：
[1]Jiang-Yi Wang;Guo-Peng Yu;Long Li;Guo-Wen Lin;Ding-Wei Ye-.Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate)[J].军事医学研究（英文）,2022(06):754-756
A类：
abiraterone,westernized,Abiraterone
B类：
Early,prostate,specific,antigen,decline,its,velocity,are,independent,predictive,factors,outcomes,mCRPC,patients,treated,acetate,Dear,Editor,
Although,incidence,cancer,PCa,has,decreased,recent,decades,countries,gradually,increased,China,due,increasingly,longer,life,expectancy,more,popular,diet,Androgen,deprivation,therapy,ADT,been,cornerstone,treatment,advanced,However,most,develop,resistance,within,median,duration,months,which,defined,castration,resistant,AA,inhibitor,androgen,biosynthesis,enzyme,CYP17,hydroxylase,C17,lyase,approved,metastatic,although,not,benefit,from,Therefore,identifying,who,will,respond,second,great,importance
AB值：
0.649159
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
